AbbVie's 3 Biggest Opportunities
AbbVie , a dividend-paying pharmaceutical company best known for its blockbuster drug Humira, is closing in on its first-year anniversary. After being spun off from Abbott Labs at the start of 2013, many investors questioned the company's future given Humira's 2016 patent expiration date. However, there are a number of signs that it does, in fact, have many opportunities to grow.
In the following video, analyst Max Macaluso breaks down three of AbbVie's biggest opportunities, including its experimental hepatitis C treatment, expanding Humira's label, and its partnerships with smaller biotech companies.
9 rock-solid dividend stocks to watch
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.
The article AbbVie's 3 Biggest Opportunities originally appeared on Fool.com.Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.